SecBot SecBot

SIBN

SI-BONE, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001459839 Healthcare & Medical Devices
$20.70 −0.78 (−3.63%)
Oct 26 4:00 PM ET · prev $21.48
Market cap
$966.3M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$25.00
+21% · range $20.00–32.00
Next earnings
Nov 2
in 7 days · EPS est. −$0.13
1 year
+32.2%
from $15.66 · Oct 27
30 days
+10.3%
from $18.76
52-week range
$11.61–21.56
−4% from high · low May 11
Avg volume 20D
566.5K
shares / day
Short interest
5.12M
≈11.4% of shares · −13.5%
Days to cover
8.7
at average volume
Insider net
-$4.9M
0 buyers · 5 sellers · since May 18
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 8 reports · 90 days
Balance 2 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 2, 2026
Strongest BEARISH CEO Laura Francis and CFO/COO Anshul Maheshwari sold a combined ~$1.84M in open-market SIBN shares over a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S May 28 to Jun 5 3 days of insider sells: $158.7K by 2 insiders, avg $14.62
  • S Jul 2 2 insiders sell $108.0K at $16.74
  • A Jul 28 UBS initiates
  • S Aug 3 1 insider sell $369.2K at $18.46
  • S Aug 17 to Aug 24 5 days of insider sells: $2.4M by 3 insiders, avg $19.52
  • R Aug 26 CEO Laura Francis and CFO/COO Anshul Maheshwari sold a combined ~$1.…
  • S Sep 1 1 insider sell $378.2K at $18.91
  • S Oct 1 to Oct 12 4 days of insider sells: $1.3M by 4 insiders, avg $19.38

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $4.9M.

  • InstitutionsBULLISH

    Q2 2026: 19 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Median target $25.00 (+21%).

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.130 → −$0.128 over 90 days. 1 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest −13.5% to 5.12M shares. 8.7 days to cover, ≈11.4% of shares.

  • TrendUPTREND

    8% above its 50-day average. New closing high $21.56 on Oct 22.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED690,288$11.3M
VANGUARD PORTFOLIO MANAGEMENT LLCADD548,287$8.9M
GOLDMAN SACHS GROUP INCTRIM441,912$7.2M
UBS Group AGDOUBLED131,779$2.2M
MORGAN STANLEYNEAR_EXIT130,913$2.1M
Squarepoint Ops LLCADD118,128$1.9M
CITIGROUP INCADD90,304$1.5M
PRICE T ROWE ASSOCIATES INC /MD/ADD66,255$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy10Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is inside the target range. Median implies +21%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Aug 4, 2026UBS
MAINTAIN
MAINTAINBuy
Aug 4, 2026Truist Securities
REITERATE
REITERATEBuy
Aug 4, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Jul 28, 2026UBS
INITIATE
INITIATEBuy
Jul 16, 2026Truist Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$4.9M
sold · 5 insiders
DateInsiderTypeValue
Oct 12, 2026
FRANCIS LAURA
Chief Executive Officer
SELL$762.0K
Oct 5, 2026
Maheshwari Anshul
Chief Op & Financial Officer
SELL$33.8K
Oct 2, 2026
PISETSKY MICHAEL A.
SVP, Ops & Adm/Chief Legal Ofr
SELL$616.76
Oct 2, 2026
Maheshwari Anshul
Chief Op & Financial Officer
SELL$32.0K
Oct 2, 2026
PISETSKY MICHAEL A.
SVP, Ops & Adm/Chief Legal Ofr
SELL$32.6K
Oct 2, 2026
Maheshwari Anshul
Chief Op & Financial Officer
SELL$28.3K
Oct 2, 2026
PISETSKY MICHAEL A.
SVP, Ops & Adm/Chief Legal Ofr
SELL$23.7K
Oct 1, 2026
DUNN JEFFREY W
Director
SELL$369.4K

Earnings setup

Estimates
Nov 2
reports in 7 days
−$0.13
EPS estimate, this quarter
+1%
estimate change, 90 days
1↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.17–-$0.08+0.0%$55.3M
Next Q-$0.07-$0.11–-$0.02+0.0%$68.2M
Current FY-$0.40-$0.45–-$0.36+0.0%$232.1M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
5,116,241
shares short
-13.5%
vs prior settlement
8.7
days to cover
≈11.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
SI-BONE, Inc. announced it will report its Q3 2026 results on November 2, 2026.
PRESS-RELEASE — Impact 1/10
Oct 19, 2026 Earnings
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in
Oct 13, 2026 SEC
Director Laura Francis (via the David & Laura Francis Joint Revocable Trust) filed a Form 144 notice of intent to sell…
144 — Impact 2/10
Oct 12, 2026 Insider
FRANCIS LAURA sold 38,006 shares
Chief Executive Officer @ $20.05 ($762.0K)
Oct 5, 2026 Insider
Maheshwari Anshul sold 1,731 shares
Chief Op & Financial Officer @ $19.50 ($33.8K)
Oct 2, 2026 Insider
PISETSKY MICHAEL A. sold 34 shares
SVP, Ops & Adm/Chief Legal Ofr @ $18.14 ($616.76)
Aug 26, 2026 SEC
CEO Laura Francis and CFO/COO Anshul Maheshwari sold a combined ~$1.84M in open-market SIBN shares over a 5-day window…
CLUSTER — Impact 6/10
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — DOUBLED
690,288 shares ($11.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
SIBN Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Oct 19, 2026
Earnings
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address…
Sep 28, 2026
Press release
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD)…
Aug 3, 2026
Earnings
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~ 15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
Aug 3, 2026
Earnings date
SIBN Q2 2026 Earnings Scheduled — 2026-08-03
Jun 4, 2026
Press release
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address…

SecBot reports

14 filings · 3 bullish · 2 bearish · 9 neutral
All SIBN filing & press-release reports (14)